Nemucore Medical Innovations, Inc. Awarded SBIR Grant for Development Of Novel Multifunctional Nanoemulsion For Imaging And Therapy Of Ovarian Cancer

Nemucore Medical Innovations, Inc. (NMI), announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the National Cancer Institute (NCI). The NMI-300 program assesses and validates the imaging, targeting

Wellesley (I-Newswire) November 16, 2010 - Nemucore Medical Innovations, Inc. (NMI), announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the National Cancer Institute (NCI). The NMI-300 program assesses and validates the imaging, targeting, cytotoxicity and pharmacokinetics of novel multifunctional nanoemulsions containing lipophilic platinum-derivatives alone or in combination with the pro-apoptopic molecules.

Today 70% of patients with advanced ovarian cancer will achieve clinically complete remission with first line treatments of carboplatin and paclitaxel. Unfortunately a majority these patients are destined to relapse and eventually die of disease due to a persistence of chemoresistant cells which metastasize throughout the body. Our overarching strategy addresses the major failures of the first line therapy and diagnostics by using multifunctional nanoemulsions to target, image, and eradicate chemosensitive and chemoresistant tumor cells. This SBIR program will extend prior rodent studies and move the technology one step closer to clinical utility.

NMI has created a consortium of partners that will support the program, including Northeastern University, and The Nanotechnology Characterization Laboratory.

NMI President and CEO Dr. Tim Coleman states that this work will make an impact on patient care, "Nanomedicine development is at its nascent stage, and the focus of NMI's work is on developing novel concepts into life saving products."

Mansoor Amiji, Distinguished Professor and Chair, Department of Pharmaceutical Sciences, at Northeastern University's School of Pharmacy, Bouve College of Health Sciences, and NMI co-founder , developed the initial technology that has been licensed by NMI . Prof Amiji said, "The improved bioavailability of these nanonemulsions will significantly extend the therapeutic impact to chemoresistant ovarian cancer cells. Advancing translation research of these safe and effective multifunctional nanoemulsions is urgently needed to create products with enhanced clinical utility."

About Nemucore Medical Innovations

Nemucore Medical Innovations, Inc. is dedicated to the development and commercialization of life-sav nanomedicines for the treatment of MDR cancers. We accomplish this objective by conceiving, testing and manufacturing nanomedicines, applying our proprietary nanoformulation technologies to drugs that need improved delivery solutions. NMI was founded in 2008 and is based in Worcester and Wellesley.Less..

Contact Information

Nemucore Medical Innovations
33 Kirkland Circle
Wellesley, MA
Phone : (617) 285-3561

Published in:

Science and Research

Published On:

November 16, 2010

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.

Related Releases

Tomsk Scientists Have Developed a Nanoceramic Analog of the Natural Bones
The scientists of Tomsk State University have completed the development of prostheses to replace small finger joints, using a nanoceramic material.

Leaving A Legacy? Honoring Someone Important? We Have Your Answer.
When choosing a gift for an event, or holiday, there is now an option that makes both the giver and receiver look more intelligent.

LDC Forms Early Drug Discovery Alliance with Daiichi Sankyo
Utilizing shared compound libraries for novel LDC targets.lead discovery center, ldc, daiichi sankyo

Gamry Instruments Launches New Online Shopping Site
Electrochemical Instruments hardware, parts and accessories now available online from Gamry Instruments.

Florida Health Equity Research Institute Established to Identify and Address Health Disparities
Collaboration of Florida's largest universities and health and government organizations serve as the go-to resource for Florida health equity researchers, students, healthcare professionals and the community.